Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Autor: Marina Chiara Garassino, Byoung-Chul Cho, Joo-Hang Kim, Julien Mazières, Johan Vansteenkiste, Hervé Lena, Jesus Corral Jaime, Jhanelle E Gray, John Powderly, Christos Chouaid, Paolo Bidoli, Paul Wheatley-Price, Keunchil Park, Ross A Soo, Yifan Huang, Catherine Wadsworth, Phillip A Dennis, Naiyer A Rizvi, Luis Paz-Ares Rodriguez, Silvia Novello, Sandrine Hiret, Peter Schmid, Eckart Laack, Raffaele Califano, Makoto Maemondo, Sang-We Kim, Jamie Chaft, David Vicente Baz, Thierry Berghmans, Dong-Wan Kim, Veerle Surmont, Martin Reck, Ji-Youn Han, Esther Holgado Martin, Cristobal Belda Iniesta, Yuichiro Oe, Antonio Chella, Akhil Chopra, Gilles Robinet, Hector Soto Parra, Michael Thomas, Parneet Cheema, Nobuyuki Katakami, Wu-Chou Su, Young-Chul Kim, Juergen Wolf, Jong-Seok Lee, Hideo Saka, Michele Milella, Inmaculada Ramos Garcia, Anne Sibille, Takashi Yokoi, Eun Joo Kang, Shinji Atagi, Ernst Spaeth-Schwalbe, Makoto Nishio, Fumio Imamura, Nashat Gabrail, Remi Veillon, Sofie Derijcke, Tadashi Maeda, Dylan Zylla, Kendra Kubiak, Armando Santoro, Ma. Noemi Uy, Sarayut Lucien Geater, Antoine Italiano, Dariusz Kowalski, Fabrice Barlesi, Yuh-Min Chen, David Spigel, Busyamas Chewaskulyong, Ramon Garcia Gomez, Rosa Alvarez Alvarez, Chih-Hsin Yang, Te-Chun Hsia, Fabrice Denis, Hiroshi Sakai, Mark Vincent, Koichi Goto, Joaquim Bosch-Barrera, Glen Weiss, Jean-Luc Canon, Christian Scholz, Massimo Aglietta, Hirotsugu Kemmotsu, Koichi Azuma, Penelope Bradbury, Ronald Feld, Abraham Chachoua, Jacek Jassem, Rosalyn Juergens, Ramon Palmero Sanchez, Albert Malcolm, Nandagopal Vrindavanam, Kaoru Kubota, Cornelius Waller, David Waterhouse, Bruno Coudert, Zsuzsanna Mark, Miyako Satouchi, Gee-Chen Chang, Christian Herzmann, Arvind Chaudhry, Selvaraj Giridharan, Paul Hesketh, Norihiko Ikeda, Ralph Boccia, Nichola Iannotti, Missak Haigentz, John Reynolds, John Querol, Kazuhiko Nakagawa, Shunichi Sugawara, Eng Huat Tan, Tomonori Hirashima, Scott Gettinger, Terufumi Kato, Koji Takeda, Oscar Juan Vidal, Andrea Mohn-Staudner, Amit Panwalkar, Davey Daniel, Kunihiko Kobayashi, Guia Elena Imelda Ladrera, Clemens Schulte, Martin Sebastian, Marketa Cernovska, Helena Coupkova, Libor Havel, Norbert Pauk, Joginder Singh, Shuji Murakami, Tibor Csoszi, Gyorgy Losonczy, Allan Price, Ian Anderson, Mussawar Iqbal, Vamsee Torri, Erzsebet Juhasz, Saleem Khanani, Leona Koubkova, Benjamin Levy, Ray Page, Csaba Bocskei, Lucio Crinò, David Einspahr, Christopher Hagenstad, Necy Juat, Lindsay Overton, Mitchell Garrison, Zsuzsanna Szalai

Publikováno v: Lancet Oncology
Lancet Oncology, 2020, 19 (4), pp.521-536. ⟨10.1016/s1470-2045(18)30144-x⟩
Lancet Oncol

Background: Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic lymphoma kinase (ALK) genetic aberrations (EGFR−/ALK−), but clinical bene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00025c91c5f85bf7d8b98d17aae85fd1
https://hal.u-pec.fr/hal-04145965/document

Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: Mature results of the Spanish Lung Cancer Group 0008 study

Autor: Rosa Morera, Ramon Garcia-Gomez, Rafael Rosell, Ana Perez-Casas, Francisco Andreu, Felipe A. Calvo, Felipe Cardenal, A. Ramos, Manuel Domine, Bartomeu Massuti, Manuel Cobo, María del Mar Arnaiz, Raquel Delgado, Antonio Arellano, Javier Valencia, Javier Zamora, Teresa Moran, Dolores Isla, Pilar Garrido

Publikováno v: Lung Cancer. 81:84-90

The optimal schedule and regimen of chemotherapy (CT) in association with chemoradiation has not been established in stage III non-small-cell lung cancer (NSCLC). We have compared three schedules of non-platinum-based CT plus either radiotherapy or c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a2eb7c9703c2a35cbe88dc135afb048
https://doi.org/10.1016/j.lungcan.2013.03.009

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

Autor: Niki, Karachaliou, Clara, Mayo-de las Casas, Cristina, Queralt, Itziar, de Aguirre, Boris, Melloni, Felipe, Cardenal, Ramon, Garcia-Gomez, Bartomeu, Massuti, José Miguel, Sánchez, Ruth, Porta, Santiago, Ponce-Aix, Teresa, Moran, Enric, Carcereny, Enriqueta, Felip, Isabel, Bover, Amelia, Insa, Noemí, Reguart, Dolores, Isla, Alain, Vergnenegre, Filippo, de Marinis, Radj, Gervais, Romain, Corre, Luis, Paz-Ares, Daniela, Morales-Espinosa, Santiago, Viteri, Ana, Drozdowskyj, Núria, Jordana-Ariza, Jose Luis, Ramirez-Serrano, Miguel Angel, Molina-Vila, Rafael, Rosell

Publikováno v: JAMA oncology. 1(2)

Importance The EURTAC trial demonstrated the greater efficacy of erlotinib compared with chemotherapy for the first-line treatment of European patients with advanced non–small-cell lung cancer (NSCLC) harboring oncogenic epidermal growth factor rec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7066c5d84281c0de275abb0fede9be54
https://pubmed.ncbi.nlm.nih.gov/26181013

Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer

Autor: B. Massuti, Enrique Aranda, Alfredo Carrato, Nieves Díaz-Fernández, Antonio Antón, Ramon Garcia-Gomez, José Jurado Sánchez, Carlos Camps, Rafael Rosell, María L. García-Paredes

Publikováno v: Lung Cancer. 17:261-269

After a 26% response rate was reported with a 20/mg/m2/week vinorelbine (VRL) dose, a multicenter phase II trial of a modified weekly VRL treatment protocol (30 mg/m2 days 1 and 8 every 21 days) for unresectable non-small cell lung cancer (NSCLC) was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4314efc1fff3119e674b560fa8d68e7d
https://doi.org/10.1016/s0169-5002(97)00029-9

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients

Autor: Dolores Isla, M. Botia, Jose Javier Sanchez, Ramon Garcia-Gomez, Vicente Alberola, B. Massuti, F.L. Cecere, Pedro Mendez, Carlos Camps, M. Cobo, Miquel Taron, R. de las Peñas, Cristina Queralt, Rafael Rosell, Maria Sanchez-Ronco, R. Garcia-Carbonero, Mariacarmela Santarpia

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 17(4)

Background: Impaired DNA repair capacity may favorably affect survival in cisplatin/gemcitabine-treated non-small-cell lung cancer (NSCLC) patients. We investigated the association of survival with genetic polymorphisms in X-ray repair cross-compleme

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb3fca6d345d13a28583d718f4c0a845
https://pubmed.ncbi.nlm.nih.gov/16407418